ArticlePharmacoEconomics2015
Do Statins Reduce the Health and Health Care Costs of Obesity?
Article in PharmacoEconomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Medication use and mammographic breast density.Breast cancer research and treatment · 2021Article
- Associations between Central Obesity and Outcomes of Adult In-hospital Cardiac Arrest: A Retrospective Cohort Study.Scientific reports · 2020Article
- Measuring The Lifetime Costs Of Serious Mental Illness And The Mitigating Effects Of Educational Attainment.Health affairs (Project Hope) · 2019Article
- In-home obesity prevention in low-income infants through maternal and social transmission.Contemporary clinical trials · 2019Article
- Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities.JACC. Heart failure · 2018Article
- PCSK9 Inhibitors Show Value for Patients and the US Health Care System.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017Article
- The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.PloS one · 2016Article
- For a Step Change to Curb the Obesity Epidemic.PharmacoEconomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
contextObesity impacts both individual health and, given its high prevalence, total health care spending. However, as medical technology evolves, health outcomes for a number of obesity-related illnesses improve. This article examines whether medical innovation can mitigate the adverse health and spending associated with obesity, using statins as a case study. Because of the relationship between obesity and hypercholesterolaemia, statins play an important role in the medical management of obese individuals and the prevention of costly obesity-related sequelae.
methodsUsing well-recognized estimates of the health impact of statins and the Future Elderly Model (FEM)-an established dynamic microsimulation model of the health of Americans aged over 50 years-we estimate the changes in life expectancy, functional status and health care costs of obesity due to the introduction and widespread use of statins.
resultsLife expectancy gains of statins are estimated to be 5-6 % greater for obese individuals than for healthy-weight individuals, but most of these additional gains are associated with some level of disability. Considering both medical spending and the value of quality-adjusted life-years, statins do not significantly alter the costs of class 1 and 2 obesity (body mass index [BMI] ≥30 and ≥35 kg/m(2), respectively) and they increase the costs of class 3 obesity (BMI ≥40 kg/m(2)) by 1.2 %.
conclusionsAlthough statins are very effective medications for lowering the risk of obesity-associated illnesses, they do not significantly reduce the costs of obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.